Publications & Presentations

October 1, 2010

PresentationTivozanib

IKCS 2010: Effect of Hypertension, Nephrectomy, and Prior Treatment on the Efficacy of Tivozanib (AV-951) in a Phase 2 Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma

October 1, 2010

PresentationTivozanib

IKCS 2010: Activity of Tivozanib (AV-951) in Patients With Different Histologic Subtypes of Renal Cell Carcinoma

September 29, 2010

Publication

GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling

Authors: Ailin Bai, Kristan Meetze, Nhi Y. Vo, Sriram Kollipara, Elizabeth K. Mazsa, William M. Winston, Solly Weiler, Laura L. Poling, Ting Chen, Nesreen S. Ismail, Jinwei Jiang, Lorena Lerner, Jeno Gyuris, Zhigang Weng. Click here for link to article.

June 7, 2010

PresentationTivozanib

ASCO 2010: Activity of Tivozanib (AV-951) in Patients With Renal Cell Carcinoma (RCC): Subgroup Analysis From a Phase 2 Randomized Discontinuation Trial (RDT)

June 5, 2010

PresentationFiclatuzumab

ASCO 2010: Phase 1 Study of SCH 900105, an Anti-Hepatocyte Growth Factor Monoclonal Antibody, as a Single Agent and in Combination with Erlotinib in Patients with Advanced Solid Tumors

March 5, 2010

PresentationTivozanib

ASCO GU 2010: Effect of hypertension, nephrectomy and prior treatment on the efficacy of tivozanib (AV-951) in a phase 2 randomized discontinuation trial (RDT) in patients with renal cell carcinoma (RCC)